Archives

Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 2024

Oxford BioTherapeutics

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, announces it has been recognized as the ‘Tech SME of the Year’ at the sixth annual Thames Valley Tech & Innovation Awards 2024. These awards celebrate the achievements of a diverse range of leading businesses from across the region.

OBT was declared a winner in recognition of its outstanding achievements in technology innovation, scientific excellence and commitment to improving patient outcomes as well as OBT’s industry leadership position and its significant progress as a key player in the ADC and T-Cell Engager space.

Also Read: Portal Biotechnologies and Multiply Labs Announce Partnership to Automate Cell Engineering In Cell Therapy Manufacturing 

The ‘Tech SME of the Year Award’ recognises exceptional use of technology to advance company objectives, improve communities and/or empower clients. OBT received this award for its ongoing efforts and application of cutting-edge technology approaches – including the launch of its enhanced proprietary OGAP®-Verify, mass spectrometry and analytical biochemistry – in order to develop new therapeutics to treat unmet needs in cancer. Notably, OBT’s own clinical assets have successfully been enabled through the OGAP® discovery platform and collaborations utilizing this platform have resulted in multipe fruitful partnerships with industry leaders, further validating the strength and versatility of its target discovery technology.

Dr. Christian Rohlff, Chief Executive Officer, said: “We are incredibly honored to be recognized as the Best Tech SME of the Year by Thames Valley Tech & Innovation Awards. This award is a testament to the hard work and dedication of OBT’s entire team, who are committed to developing innovative therapies to treat cancer. This year’s recognition highlights the significant technological advancements of our discovery database, OGAP®-Verify, which aims to increase the chances of success in cancer treatments. This honor inspires us to continue our mission of driving innovation and excellence for cancer patients.”

Last year, OBT received the ‘Tech Company of the Year’ as well as the ‘Special Recognition’ awards at the Annual Thames Valley SME Growth 100 Awards, further cementing its reputation as a pioneer and leader of innovation in technology in the region.

SOURCE: GlobeNewswire